BRCA1 gene mutation associated with neoadjuvant chemotherapy

Nearly half of breast cancer patients carrying the BRCA1 gene mutation experience a complete pathological response (pCR) – the disappearance of all evidence of disease from the breast tissue and lymph nodes – regardless of disease stage after standard neoadjuvent chemotherapy, according to new research from The University of Texas MD Anderson Cancer Center.

Read the whole article on Physorg

More from Physorg